Recombinant Human CD147 Protein，His

CD147, also known as basigin or extracellular matrix metalloproteinase inducer (EMMPRIN), is a transmembrane glycoprotein that plays a critical role in various physiological and pathological processes, including cell adhesion, migration, and tumor metastasis. Its expression is upregulated in various cancers, making it a significant target for cancer therapy and diagnostics. Research has shown that CD147 interacts with matrix metalloproteinases (MMPs) and promotes their secretion, facilitating extracellular matrix remodeling and tumor invasion. Additionally, CD147 is involved in the immune response and is implicated in conditions such as inflammation, autoimmune diseases, and viral infections, including HIV and COVID-19. The generation of recombinant CD147 proteins has been vital for elucidating its biological functions, molecular mechanisms, and potential therapeutic applications. By producing and characterizing recombinant CD147, researchers aim to better understand its role in disease progression and explore its utility as a biomarker or therapeutic target. The study of CD147 also provides insights into its structure-function relationship and its interactions with other proteins, opening avenues for the development of CD147-targeted therapies that could inhibit tumor growth and improve patient outcomes. Overall, the ongoing research on CD147 recombinant proteins is crucial for advancing our understanding of this multifunctional protein and its implications in health and disease.